Lexeo Therapeutics (LXEO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Lexeo Therapeutics (LXEO) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.13 of bullish evidence against -0.35 bearish.

Lexeo Therapeutics last closed at $3.41, -3.40% on the session.

Against the IVW growth benchmark the position is -4.32% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

16 graded predictions for LXEO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Lexeo Therapeutics in the 20th percentile on return on equity, where 100 is best.

Lexeo Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $289.78M.

StockMap tracks Lexeo Therapeutics as the 198th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Lexeo Therapeutics ranks 236th of 344 in the group, against a group median of -0.21.